Thursday, February 23, 2017 7:26:31 PM
2 patients were partial responders and 1 patient had a complete response by the 9th month of treatment. The 1 partial responder is only at the 6 month stage so may become a complete responder with further treatments. The 1 partial responder at 12 months seems to be responding slower than the other responders. So this could mean that patients that do respond to the combo therapy are slowly becoming complete responders by the one year mark.
The 2 partial responders are continuing on so the next data readout will be critical.
It is amazing that Oncosec is getting a response in patients that have 100% failure to pd-1 monotherapy.
This is big and the market doesn't care today. So we need more patient data going forward which I believe we will get later on in this trial which will be enough positive data to get the green light for the registration trial.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM